Norman E Lee

US Patent:

6383793, May 7, 2002

Filed:

Aug 20, 1997

Appl. No.:

08/915095

Inventors:

Gregg A. Hastings - Rockville MD
Mark D. Adams - Potomac MD
Claire M. Fraser - Gueenstown MD
Norman H. Lee - Woodstock MD
Ewen F. Kirkness - Washington DC
Judith A. Blake - Laurel MD
Lisa M. Fitzgerald - Germantown MD
Fred H. Drake - Glenmoore PA
Maxine Gowan - Valley Forge PA

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C12N 964

US Classification:

435226, 435183, 435212, 4352523, 4353201, 435325, 43525411, 435 691, 536 231, 536 232, 536 235

Abstract:

Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

US Patent:

6387682, May 14, 2002

Filed:

Feb 12, 1997

Appl. No.:

08/798096

Inventors:

Gregg A. Hastings - Rockville MD
Mark D. Adams - Potomac MD
Claire M. Fraser - Gueenstown MD
Norman H. Lee - Woodstock MD
Ewen F. Kirkness - Washington DC
Judith A. Blake - Laurel MD
Lisa M. Fitzgerald - Germantown MD
Fred H. Drake - Glenmoore PA
Maxine Gowan - Valley Forge PA

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C12N 964

US Classification:

435226, 435183, 435212, 435 691, 4353201, 4352523, 530350, 514 1, 514525

Abstract:

Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

US Patent:

6423507, Jul 23, 2002

Filed:

Feb 12, 1997

Appl. No.:

08/798095

Inventors:

Gregg A. Hastings - Rockville MD
Mark D. Adams - Potomac MD
Claire M. Fraser - Gueenstown MD
Norman H. Lee - Woodstock MD
Ewen F. Kirkness - Washington DC
Judith A. Blake - Laurel MD
Lisa M. Fitzgerald - Germantown MD
Fred H. Drake - Glenmoore PA
Maxine Gowan - Valley Forge PA

Assignee:

Human Genome Sciences, Inc. - Rockville MD
Smithkline Beecham Corporation - Philadelphia PA

International Classification:

C12Q 137

US Classification:

435 23, 435219, 435226, 435 4, 435183

Abstract:

Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

US Patent:

6475766, Nov 5, 2002

Filed:

Nov 7, 1995

Appl. No.:

08/553125

Inventors:

Gregg A. Hastings - Rockville MD
Mark D. Adams - Potomac MD
Claire M. Fraser - Gueenstown MD
Norman H. Lee - Woodstock MD
Ewen F. Kirkness - Washington DC
Judith A. Blake - Laurel MD
Lisa M. Fitzgerald - Germantown MD
Fred H. Drake - Glenmoore PA
Maxine Gowan - Valley Forge PA

Assignee:

Human Genome Sciences, Inc. - Rockville MD
SmithKline Beecham Corporation - Philadelphia PA

International Classification:

C12N 964

US Classification:

435226, 435212, 435183, 435 691, 4353201, 4352523, 530350, 514 1, 514525

Abstract:

Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

US Patent:

55019692, Mar 26, 1996

Filed:

Mar 8, 1994

Appl. No.:

8/208007

Inventors:

Gregg A. Hastings - Rockville MD
Mark D. Adams - Potomac MD
Claire M. Fraser - Gueenstown MD
Norman H. Lee - Woodstock MD
Ewen F. Kirkness - Washington DC
Judith A. Blake - Laurel MD
Lisa M. Fitzgerald - Germantown MD
Fred H. Drake - Glenmoore PA
Maxine Gowan - Valley Forge PA

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C12N 1557
C12N 1563
C12N 121
C12N 510

US Classification:

4352402

Abstract:

Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

US Patent:

58612980, Jan 19, 1999

Filed:

May 7, 1997

Appl. No.:

8/852807

Inventors:

Mark D. Adams - North Potomac MD
Judith A. Blake - Laurel MD
Christine M. Debouck - Wayne PA
Fred H. Drake - Glenmoore PA
Lisa M. Fitzgerald - Germantown MD
Claire M. Fraser - North Potomac MD
Maxine Gowen - Valley Forge PA
Gregg A. Hastings - Thousand Oaks CA
Ewen F. Kirkness - Olney MD
Norman H. Lee - Woodstock MD
Julie Rood - Lansdowne PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA
Human Genome SciencesInc - Rockville MD

International Classification:

C12N 1511
C12N 1557
C12N 1563
C12P 2102

US Classification:

435226

Abstract:

The invention relates to cathepsin K polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

US Patent:

20150252432, Sep 10, 2015

Filed:

Mar 5, 2015

Appl. No.:

14/639219

Inventors:

Norman Lee - Dayton MD, US
Bi-Dar Wang - Potomac MD, US

International Classification:

C12Q 1/68

Abstract:

A method of classifying a patient for eligibility for cancer therapy based on the presence or absence of splicing variants in a sample of the patient's cancer tissue. Also, a method of screening cancer therapies for efficacy against splicing variants. More specifically, the methods relate to novel splicing variants of genes associated with cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. Also more specifically, the methods relate to classifying a patient for eligibility for cancer therapy involving the use of GS-1101.